Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]


On page 1027, please note that on Table 1, the population for the trial GOG170D (Burger et al[34]) with 62 patients was described as “≤2 lines of previous treatment, 58% Pl resistant, 26% Pl sensitive with Pl-free interval <12 months”. However, the correct description of the population should be “≤2 lines of previous treatment, 58% Pl resistant, 42% Pl sensitive”.

OncoTargets and Therapy 2014:7 1473